125541-12-0

Basic information

• Product Name: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester
• Synonyms: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester;[1,4'-Bipiperidine]-1'-carboxylic acid 1,1-dimethylethyl ester;tert-Butyl 1,4'-bipiperidine-1'-carboxylate;[1,4'-Bipiperidine]-1'-carbonyl-1'-carboxylic Acid tert-Butyl Ester
• CAS NO: 125541-12-0
• Molecular Formula: C₁₅H₂₈N₂O₂
• Molecular Weight: 268.398
• Product Categories: Heterocycles
• Mol File: 125541-12-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(125541-12-0)
• EPA Substance Registry System: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(125541-12-0)

Safety Data

• Hazardous Substances Data: 125541-12-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting neurodegenerative diseases. Its unique structure allows for the development of inhibitors that can modulate specific biological pathways and receptors, offering potential therapeutic benefits in the treatment of conditions such as Alzheimer's, Parkinson's, and other related disorders.
Used in Agrochemical Industry:
In the agrochemical sector, [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester serves as a precursor for the development of novel pesticides and herbicides. Its chemical properties enable the creation of compounds with enhanced efficacy and selectivity, targeting specific pests or weeds while minimizing harm to non-target organisms and the environment.
Used in Chemical Research:
As a light yellow oil with distinct chemical properties, [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester is also utilized in chemical research for the exploration of new reaction pathways and the synthesis of innovative organic compounds. Its reactivity and solubility make it a valuable tool for chemists working in various fields, including materials science, medicinal chemistry, and synthetic organic chemistry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 944411-93-2 [1,4']bipiperidinyl-1'-carboxylic acid (4-bromo-phenyl)amide 
• 4897-50-1 4-piperidinopiperidin 
• 64-18-6 formic acid 
• 1608129-80-1 C₁₉H₂₂ClN₃O₄ 
• 1608129-79-8 C₁₉H₂₂ClN₃O₄ 
• 1608129-78-7 C₁₉H₂₁F₂N₃O₅ 
• 1608129-77-6 C₁₉H₂₃N₃O₅ 
• 1040724-79-5 5-amino-3-(4-methoxyphenyl)pyrazole-1-carboxylic acid tert-butyl ester 
• 110-89-4 piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 4897-50-1 4-piperidinopiperidin 
• 172281-92-4 1,4'-bipiperidine hydrochloride 

Relevant articles and documents

CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.

Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation

LRRK2IN1 is a highly potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 7.9 nM), an established target for treatment of Parkinson's disease. Two LRRK2IN1 analogues 1 and 2 were synthesised which retained LRRK2 inhibitory activity (1: IC50 = 72 nM; 2: IC50 = 51 nM), were predicted to have improved bioavailability and were efficacious in cell-based models of neuroinflammation. Analogue 1 inhibited IL-6 secretion from LPS-stimulated primary human microglia with EC50 = 4.26 μM. In order to further optimize the molecular properties of LRRK2IN1, a library of truncated analogues was designed based on docking studies. Despite lacking LRRK2 inhibitory activity, these compounds show antineuroinflammatory efficacy at micromolar concentration. The compounds developed were valuable tools in establishing a cell-based assay for assessing anti-neuroinflammatory efficacy of LRRK2 inhibitors. Herein, we present data that IL-1β stimulated U87 glioma cell line is a reliable model for neuroinflammation, as data obtained in this model were consistent with results obtained using primary human microglia and astrocytes.

Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor

α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.